PAREXEL International to Present at William Blair Emerging Growth Stock ... ( BOSTON Sept. 30 /- PAREXEL Internatio...)

PAREXEL International to Present at William Blair Emerging Growth Stock Conference

Date:9/30/2009

BOSTON, Sept. 30 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the William Blair Emerging Growth Stock Conference in New York, NY. James Winschel, Senior Vice President and Chief Financial Officer, will be making a formal presentation on PAREXEL at 3:30 p.m. EDT on Tuesday, October 6, 2009.

A live webcast of this presentation will be available under the "Upcoming Events" section on PAREXEL's "Investors" homepage at www.PAREXEL.com. A replay of the presentation will be available until November 5, 2009.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,275 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark
'/>"/>

0

GOOD

Page: 1 2
Related medicine technology :

1. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
2. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Expands Global Clinical Pharmacology Capabilities
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
7. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
8. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
9. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
10. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
11. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society

Post Your Comments:

PAREXEL International to Present at William Blair Emerging Growth Stock ...( BOSTON Sept. 30 /- PAREXEL Internatio...),Health